Utilization and Survival Impact of Definitive Hypofractionated Radiotherapy Compared to Conventionally Fractionated Radiotherapy in Stage I Non-Small Cell Lung Cancer

The real-world impact of definitive hypofractionated radiotherapy (HFRT) is unclear for patients with stage I non-small cell lung cancer (NSCLC) not suitable for surgery, stereotactic body radiation therapy (SBRT), or chemoradiotherapy. HFRT is more convenient, is less expensive, and is amenable to BED10 (biologically effective dose assuming α/β=10) escalation compared to conventionally fractionated radiotherapy (CFRT).

Source: International Journal of Radiation Oncology * Biology * Physics - September 10, 2020 Category: Radiology Authors: Henry Park, Nadia Saeed, Roy Decker Source Type: research